文献速递类风湿关节炎

自身抗体阳性类风湿关节炎持续无药缓解者免疫缓解的长期随访研究

Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
PubMed 文献 · Ann Rheum Dis · 2019-08-14

本研究长期观察95例自身抗体阳性类风湿关节炎(RA)患者达到持续无DMARD缓解后自身抗体是否消失,并与晚期复发及持续活动患者比较。结果显示持续无药缓解者抗CCP2 IgG血清转阴率13%,与复发和持续疾病者无显著差异,提示免疫缓解可能不是已确诊RA的治疗目标。

要点

  • 持续无DMARD缓解的自身抗体阳性RA患者中血清转阴率低(抗CCP2 IgG为13%)。
  • 血清转阴率在持续缓解、晚期复发和持续疾病组间无显著差异(p=0.63)。
  • RF水平在缓解组下降更明显,但抗CCP2水平变化无差异。

核心结论

  • 自身抗体阳性RA患者达到持续无DMARD缓解不伴随自身抗体转阴频率增加,免疫缓解可能不是已确诊RA的治疗目标。

研究设计与样本

  • 长期观察性研究,纳入95例达到持续无DMARD缓解的ACPA和/或RF阳性RA患者(缓解中位4.8年,随访中位4.2年),另设21例晚期复发和45例无法停用DMARD的自身抗体阳性RA患者对照,检测587份样本的anti-CCP2 IgG、IgM和RF IgM。

主要发现

  • 达到缓解时,13%的anti-CCP2 IgG阳性RA患者发生血清转阴;复发者和持续疾病者分别为8%和6%(p=0.63)。
  • anti-CCP2 IgM和RF IgM结果类似。
  • 系列检测水平估计斜率显示,缓解组RF水平下降较无缓解组更明显(p<0.001),而anti-CCP2水平变化无差异(p=0.66)。

临床怎么用

  • 对于已确诊的自身抗体阳性RA,不应将自身抗体转阴(免疫缓解)作为治疗目标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Sustained disease-modifying antirheumatic drug (DMARD)-free status, the sustained absence of synovitis after cessation of DMARD therapy, is infrequent in autoantibody-positive rheumatoid arthritis (RA), but approximates cure (ie, disappearance of signs and symptoms). It was recently suggested that immunological remission, defined as disappearance of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF), underlies this outcome. Therefore, this long-term observational study determined if autoantibodies disappear in RA patients who achieved sustained DMARD-free remission. METHODS: We studied 95 ACPA-positive and/or RF-positive RA patients who achieved DMARD-free remission after median 4.8 years and kept this status for the remaining follow-up (median 4.2 years). Additionally, 21 autoantibody-positive RA patients with a late flare, defined as recurrence of clinical synovitis after a DMARD-free status of ≥1 year, and 45 autoantibody-positive RA patients who were unable to stop DMARD therapy (during median 10 years) were studied. Anti-cyclic citrullinated peptide 2 (anti-CCP2) IgG, IgM and RF IgM levels were measured in 587 samples obtained at diagnosis, before and after achieving DMARD-free remission. RESULTS: 13% of anti-CCP2 IgG-positive RA patients had seroreverted when achieving remission. In RA patients with a flare and persistent disease this was 8% and 6%, respectively (p=0.63). For anti-CCP2 IgM and RF IgM, similar results were observed. Evaluating the estimated slope of serially measured levels revealed that RF levels decreased more in patients with than without remission (p<0.001); the course of anti-CCP2 levels was not different (p=0.66). CONCLUSIONS: Sustained DMARD-free status in autoantibody-positive RA was not paralleled by an increased frequency of reversion to autoantibody negativity. This form of immunological remission may therefore not be a treatment target in patients with classified RA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Boeters DM, Burgers LE, Toes RE, et al. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status. Ann Rheum Dis. 2019. PMID: 31413004. doi:10.1136/annrheumdis-2018-214868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。